Filtered By:
Source: Journal of Neurosurgery
Drug: Temodar
This page shows you your search results in order of date.
Order by Relevance | Date
Total 1 results found since Jan 2013.
An extent of resection threshold for recurrent glioblastoma and its risk for neurological morbidity.
Conclusions For recurrent glioblastomas, an improvement in overall survival can be attained beyond an 80% EOR. This survival benefit must be balanced against the risk of neurological morbidity, which does increase with more aggressive cytoreduction, but only in the early postoperative period. Interestingly, this putative EOR threshold closely approximates that reported for newly diagnosed glioblastomas, suggesting that for a subset of patients, the survival benefit of microsurgical resection does not diminish despite biological progression.
PMID: 24484232 [PubMed - as supplied by publisher]
Source: Journal of Neurosurgery - January 31, 2014 Category: Neurosurgery Authors: Oppenlander ME, Wolf AB, Snyder LA, Bina R, Wilson JR, Coons SW, Ashby LS, Brachman D, Nakaji P, Porter RW, Smith KA, Spetzler RF, Sanai N Tags: J Neurosurg Source Type: research
